NCT00622479View on ClinicalTrials.gov

Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

October 31, 2010

Study Completion Date

November 30, 2010

Conditions
Carcinoma, Renal Cell
Interventions
DRUG

Sorafenib (Nexavar, BAY43-9006)

Sorafenib will be administered at 400mg BID for a 28 day cycle.

Trial Locations (7)

32224

Jacksonville

48201

Detroit

55905

Rochester

60153

Maywood

85259

Scottsdale

07601

Hackensack

11794-944

Stony Brook

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00622479 - Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia. | Biotech Hunter | Biotech Hunter